BR112012002578B8 - usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística - Google Patents

usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística

Info

Publication number
BR112012002578B8
BR112012002578B8 BR112012002578A BR112012002578A BR112012002578B8 BR 112012002578 B8 BR112012002578 B8 BR 112012002578B8 BR 112012002578 A BR112012002578 A BR 112012002578A BR 112012002578 A BR112012002578 A BR 112012002578A BR 112012002578 B8 BR112012002578 B8 BR 112012002578B8
Authority
BR
Brazil
Prior art keywords
cystic fibrosis
pharmaceutically acceptable
acceptable salt
treprostinil
derivative
Prior art date
Application number
BR112012002578A
Other languages
English (en)
Other versions
BR112012002578B1 (pt
BR112012002578A2 (pt
Inventor
Gloeckel Christina
Freissmuth Michael
Koenig Xaver
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Publication of BR112012002578A2 publication Critical patent/BR112012002578A2/pt
Publication of BR112012002578B1 publication Critical patent/BR112012002578B1/pt
Publication of BR112012002578B8 publication Critical patent/BR112012002578B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição para o tratamento da fibrose cística. a presente invenção provê composições compreendendo uma prostaciclina ou análogo de prostaciclina, ou um sal ds mesma farmaceuticamente aceitável para uso na prevenção ou no tratamento de fibrose cística. a invenção também provê o uso de um kit compreendendo uma prostaciclina ou análogo de prostacilcina para tratar ou prevenir uma condição associada com fibrose cística em um sujeito.
BR112012002578A 2009-08-07 2010-08-05 usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística BR112012002578B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09167491.1 2009-08-07
EP09167491 2009-08-07
PCT/EP2010/061428 WO2011015630A1 (en) 2009-08-07 2010-08-05 Composition for the treatment of cystic fibrosis

Publications (3)

Publication Number Publication Date
BR112012002578A2 BR112012002578A2 (pt) 2016-03-15
BR112012002578B1 BR112012002578B1 (pt) 2021-01-12
BR112012002578B8 true BR112012002578B8 (pt) 2021-05-25

Family

ID=41382119

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012002578A BR112012002578B8 (pt) 2009-08-07 2010-08-05 usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística

Country Status (26)

Country Link
US (2) US20120184622A1 (pt)
EP (1) EP2461812B1 (pt)
JP (1) JP5877787B2 (pt)
KR (1) KR101729800B1 (pt)
CN (1) CN102548559B (pt)
AU (1) AU2010280684B2 (pt)
BR (1) BR112012002578B8 (pt)
CA (1) CA2770066C (pt)
CL (1) CL2012000319A1 (pt)
CY (1) CY1114983T1 (pt)
DK (1) DK2461812T3 (pt)
EA (1) EA023720B1 (pt)
ES (1) ES2451790T3 (pt)
GT (1) GT201200038A (pt)
HK (1) HK1165293A1 (pt)
HN (1) HN2012000297A (pt)
HR (1) HRP20140277T1 (pt)
IL (1) IL217899B (pt)
PL (1) PL2461812T3 (pt)
PT (1) PT2461812E (pt)
RS (1) RS53234B (pt)
SG (1) SG178315A1 (pt)
SI (1) SI2461812T1 (pt)
SM (1) SMT201400057B (pt)
WO (1) WO2011015630A1 (pt)
ZA (1) ZA201200790B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
AU2012206517B2 (en) 2011-01-13 2016-12-01 Scipharm Sarl Method for Enhancing Engraftment of Haematopoietic Stem Cells
ES2612510T3 (es) 2011-02-07 2017-05-17 Scipharm Sàrl Composición novedosa para el tratamiento de fibrosis quística
JP6542128B2 (ja) 2013-01-11 2019-07-10 コルセア ファーマ インコーポレイテッド トレプロスチニルのプロドラッグ
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
PT3060041T (pt) 2013-10-25 2021-03-12 Insmed Inc Compostos de prostaciclina
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. DRY POWDER OF TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION
KR102541885B1 (ko) 2016-09-26 2023-06-12 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드럭
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
JP2023529828A (ja) 2020-06-09 2023-07-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
KR20230134480A (ko) 2020-12-14 2023-09-21 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6310898A (en) * 1997-03-14 1998-10-12 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
AU4976599A (en) 1998-07-08 2000-02-01 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN100558351C (zh) * 2003-05-22 2009-11-11 联合治疗公司 化合物和释放前列环素类似物的方法
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
US8318802B2 (en) * 2006-02-03 2012-11-27 Actelion Pharmaceuticals Ltd. Epoprostenol formulation and method of making thereof
JP2010518122A (ja) * 2007-02-09 2010-05-27 ユナイテッド セラピューティクス コーポレーション 間質性肺疾患および喘息のためのトレプロスチニル処置

Also Published As

Publication number Publication date
ZA201200790B (en) 2013-05-29
SMT201400057B (it) 2014-07-07
HK1165293A1 (en) 2012-10-05
CA2770066A1 (en) 2011-02-10
KR101729800B1 (ko) 2017-04-24
SI2461812T1 (sl) 2014-05-30
CN102548559A (zh) 2012-07-04
AU2010280684B2 (en) 2016-07-28
CN102548559B (zh) 2013-12-25
EP2461812A1 (en) 2012-06-13
JP2013501032A (ja) 2013-01-10
HRP20140277T1 (hr) 2014-04-25
SG178315A1 (en) 2012-03-29
KR20120056819A (ko) 2012-06-04
IL217899B (en) 2018-05-31
US20160175319A1 (en) 2016-06-23
RS53234B (en) 2014-08-29
AU2010280684A1 (en) 2012-02-23
DK2461812T3 (da) 2014-04-07
US20120184622A1 (en) 2012-07-19
EP2461812B1 (en) 2014-01-01
WO2011015630A1 (en) 2011-02-10
EA023720B1 (ru) 2016-07-29
EA201200253A1 (ru) 2012-07-30
JP5877787B2 (ja) 2016-03-08
GT201200038A (es) 2015-01-16
ES2451790T3 (es) 2014-03-28
CY1114983T1 (el) 2016-12-14
CA2770066C (en) 2018-10-23
PL2461812T3 (pl) 2014-12-31
HN2012000297A (es) 2015-05-18
IL217899A0 (en) 2012-03-29
CL2012000319A1 (es) 2012-09-14
BR112012002578B1 (pt) 2021-01-12
BR112012002578A2 (pt) 2016-03-15
PT2461812E (pt) 2014-04-07
US10086001B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
BR112012002578B8 (pt) usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística
BR112014024672A8 (pt) Composições farmacêuticas para terapia de combinação
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
BR112015023412A2 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
MX2009010132A (es) Analogos de pirazolopirimidina y su uso como inhibidores de cinasa mtor y cinasa pi3.
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
MX366175B (es) Composiciones fosfolipidicas terapeuticas concentradas.
MX363178B (es) Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados.
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
MX369385B (es) Productos para cicatrizar heridas tisulares.
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BR112012000204A8 (pt) Composição farmacêutica em forma de dosagem unitária que compreende apomorfina e seu uso
ECSP13012573A (es) 6-amino-nicotinamidas sustituidas como moduladores de KCNQ2/3
UY31228A1 (es) Ariloxazoles sustituidos y su uso
HN2012000031A (es) Terapia de combinacion para el tratamiento de la diabetes
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0906444B8 (pt) compostos de 4-piridinona, composição farmacêutica que os compreende, bem como uso dos mesmos
BR112015023761A2 (pt) moduladores de molécula pequena de pcsk9 e seus métodos e usos
CL2009000246A1 (es) Compuestos derivados de 1h-imidazo[4,5-b]piridin-2-ol; moduladores de la contraccion sarcomero; composicion farmaceutica que comprende; kit farmaceutico; y uso en el tratamiento de enfermedades neuromusculares, tales como atrofia, fatiga, claudicacion, en entre otras.
TN2014000046A1 (en) Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: SCIPHARM SA RL (LU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2734 DE 30-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.